Teva Gains EMA Filing Acceptance for Olanzapine LAI TEV-'749 in Adult Schizophrenia

EMA's acceptance of Teva's Marketing Authorization Application for TEV-'749 moves a subcutaneous olanzapine long-acting injectable into formal European review for the first time, presenting formulation and manufacturing teams with a controlled-release polymer platform that differs materially from existing intramuscular LAI paradigms. The submission is backed by the Phase 3 SOLARIS study and a clinical package demonstrating systemic exposure consistent with oral olanzapine.

TEV-'749 is formulated using SteadyTeq™, a copolymer technology proprietary to Medincell designed to deliver controlled, steady, prolonged drug release via subcutaneous injection every four weeks. For process development and QA leads, the platform raises distinct considerations around polymer characterisation, release-rate reproducibility, and sterility assurance relative to conventional aqueous LAI suspensions. Demonstrating batch-to-batch consistency in copolymer-based matrices will be a central process validation requirement under ICH Q10 and applicable 21 CFR Part 211 standards should a parallel US pathway follow.

The absence of any approved long-acting olanzapine formulation to date reflects the formulation complexity the SteadyTeq™ platform is designed to resolve. Oral olanzapine remains among the most widely prescribed antipsychotics in Europe, and adherence gaps in real-world schizophrenia management are well documented. A subcutaneous once-monthly option, if approved, would require manufacturing sites to qualify new fill-finish processes and establish validated in-vitro release methods capable of predicting in-vivo performance for a polymer-matrix depot.

Schizophrenia affects between 0.3% and 1.5% of the European population, and approximately 80% of patients experience multiple relapses within the first five years of treatment. Each relapse carries documented risk of treatment refractoriness and functional decline, reinforcing the clinical rationale for adherence-supporting formulations. TEV-'749 has not received regulatory approval in any jurisdiction as of the announcement date.

The EMA review timeline will set the pace for commercial manufacturing readiness, and Teva's ability to demonstrate robust process validation data for the SteadyTeq™ platform will be a defining checkpoint before any conditional or full marketing authorisation can be granted.

Source: Teva Pharmaceutical Industries / Medincell via GlobeNewswire, 21 May 2026.